Asian Spectator


The Times

.

Josh Ferris and Justine Guerard Triumph at the 32nd Laguna Phuket Triathlon, Asia’s Longest-Running Triathlon

Australia’s Ferris and France’s Guerard conquer Phuket’s iconic resort racecourse, as international athletes battle for USD 20,000 in prize money.PHUKET, THAILAND – Media OutR...

OSL Exchange Expands Access to Institutional Investors in USA ...

CHICAGO, Dec. 8, 2021 /PRNewswire-AsiaNet/ -- -Zero trading fees offered to clients until the end of 2021 to mark OSL's North America growth -Access available through REST API, FIX 4.4 Proto...

ARTTA Concept - Local interior architectural design brand winning multiple international awards through strategic commercial design, breaking the monotony of the business world, contributing to societal design value

HONG KONG SAR - Media OutReach - 13 November 2023 - As stepping into 2023, commercial interior design may still feel "mundane and disconnected". Yet, modern architectural design can break s...

Sodra's Breakthrough Will Enable Large-scale Textile Recycling

VAXJO, Sweden, Oct. 28, 2019 /PRNewswire-AsiaNet/ -- - At present, no one in the world can recycle fibres from blended fabrics on a large scale. Sodra now has a unique solution that will ena...

De Beers Group Doubles Down On Natural Diamonds With the Return of the Iconic ‘A Diamond is Forever’ Category Campaign

Additional $20 million investment includes the return of 'Seize the Day' advertising reimagined for the 2023 holiday seasonLightbox ends LGD engagement ring test HONG KONG SAR - Media OutRe...

Avance Clinical Awarded Frost Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership

ADELAIDE, AUS, Aug 10, 2021 - (ACN Newswire) - Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asi...

As Thailand Reopens, Malls Welcome Shoppers to The New Normal

BANGKOK, May18, 2020 /PRNewswire-AsiaNet/ -- As Thailand gradually reopened on Sunday May 17th following the country's successful control of the COVID-19 outbreak, Bangkok's flagship malls a...

INOVIO Announces Positive Data from Phase 2 Segment of Clinica...

PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire-AsiaNet/ -- -- INO-4800 was shown to be safe, well-tolerated and immunogenic in allage groups-- Phase 2 results informed INOVIO's selection of...

Fleet Complete Vision(TM) Brings Intelligent Video Analytics t...

TORONTO, April 5, 2018 /PRNewswire-AsiaNet/ -- -- New real-time video analytics solution, Fleet Complete Vision(TM), combines mobile video technology with telematics data to enhance fleet sa...

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

HONG KONG, May 26, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug (generic name: Penpulimab; R&D code: AK105) jointly developed and commercialized with Akeso, Inc. (HKEX: 9926), a biopharmaceutical company committed to R&D, production and commercialization of affordable innovative antibody drugs for patients worldwide, has been accepted by the National Medical Products Administration of the PRC, for the treatment of patients with relapsed or refractory Classical Hodgkin's Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age . cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%. Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment .

Professor Zhu Jun, Co-principal investigator of the lead unit Beijing Cancer Hospital is full of expectations for such a differentiated anti PD-1 monoclonal product and said, through bioengineering technology, Penpulimab completely eliminate the binding activity of Fc receptors and avoid the antibody-dependent cell-mediated cytotoxicity (ADCC) effect. At the same time, compared with other drugs available in the market working on the same target, it has a slower rate of antigen binding and dissociation, which makes the biological effect stronger and improves its anti-tumor activity.

Co-lead researcher Professor Song Yuqin, Director of Lymphoma Department at Peking University Cancer Hospital said, in clinical trial, Penpulimab was observed with gratifying therapeutic data and good safety. As a clinician, Professor Song hoped that Penpulimab can be launched to the market soon, which will benefit more patients and their families.

About Sino Biopharmaceutical Limited (HKEX: 1177)Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng Index - Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index - Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018. http://www.sinobiopharm.com/.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/güvenilir bahis siteleriStreamEastStreamEastjojobet